BioCentury
ARTICLE | Clinical News

HVJ-E: Phase I/II start

October 10, 2011 7:00 AM UTC

AnGes said this month investigators will begin an open-label, Japanese Phase I/II trial evaluate intratumoral and subcutaneous injections of HVJ-E in 12 CRPC patients. In 2009, AnGes' GenomIdea Inc. ...